摘要 |
The invention relates to products having formula (I), wherein: R1 denotes pyrazolyl or indazolyl; R2 and R3 denote H, halogen, hydroxyl, nitro, cyano, R4, -OR4, -COR4, -OC(=O)R4, -C(=O)OR4, -C(=O)OH, -N(R5)C(=O)R4, -N(R5)C(=O)OR4, -S(O)nR4, -S(O)nOR4, -N(R5)SO2R4, -NY1Y2, -C(=O)NY1Y2, -N(R5)C(=O)NY1Y2, -S(O)nNY1Y2 and -OC(=O)NY1Y2; R4 denotes, for example, alkyl, alkenyl, cycloalkyl, aryl, heteroaryl, heterocycloalkyl; R5 denotes, for example, H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; Y1 and Y2 denote, for example, H, alkyl, alkenyl, cycloalkyl, heterocycloalykl, aryl, arylcarboxy, heteroaryl and heteroarylcarboxy, and are optionally substituted, or Y1 and Y2 together with N form an amine cycle; and n denotes 0 to 2, all of said radicals being optionally substituted. The invention relates to the use of the aforementioned products in all isomeric forms and the salts thereof as medicaments, particularly as KDR inhibitors. |